HALOZYME THERAPEUTICS, INC. Payments to Acquire Debt Securities, Available-for-sale
HALOZYME THERAPEUTICS, INC. (HALO) reported Payments to Acquire Debt Securities, Available-for-sale of $120.61 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2026-08-06
- HALOZYME THERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2026-06-30 was $111.76M, a 8.76% increase year-over-year.
- HALOZYME THERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2026-03-31 was $8.85M, a 93.67% decline year-over-year.
- HALOZYME THERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- HALOZYME THERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2025-09-30 was $4.96M, a 98.37% decline year-over-year.
- HALOZYME THERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for fiscal 2025 was $247.35M, a 61.80% decline from fiscal 2024.
- HALOZYME THERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for fiscal 2024 was $647.60M, a 121.09% increase from fiscal 2023.
- HALOZYME THERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for fiscal 2023 was $292.91M, a 14.77% increase from fiscal 2022.
- HALOZYME THERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for fiscal 2022 was $255.21M, a 60.89% decline from fiscal 2021.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2026-06-30 | $111.76M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $120.61M 10-Q · filed 2026-08-06 | $120.61M derived: sum of 3 quarters · filed 2026-08-06 | $125.56M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $8.85M 10-Q · filed 2026-05-11 | $8.85M derived: sum of 2 quarters · filed 2026-05-11 | $13.80M derived: sum of 3 quarters · filed 2026-05-11 | $116.56M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $4.96M derived: sum of 2 quarters · filed 2026-02-17 | $107.72M derived: sum of 3 quarters · filed 2026-08-06 | $247.35M 10-K · filed 2026-02-17 |
| 2025-09-30 | $4.96M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $107.72M derived: sum of 2 quarters · filed 2026-08-06 | $247.35M 10-Q · filed 2025-11-03 | $298.80M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $102.76M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $242.40M 10-Q · filed 2026-08-06 | $293.84M derived: sum of 3 quarters · filed 2026-08-06 | $597.82M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $139.64M 10-Q · filed 2026-05-11 | $191.08M derived: sum of 2 quarters · filed 2026-05-11 | $495.06M derived: sum of 3 quarters · filed 2026-05-11 | $588.48M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $51.44M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $355.42M derived: sum of 2 quarters · filed 2026-02-17 | $448.84M derived: sum of 3 quarters · filed 2026-02-17 | $647.60M 10-K · filed 2026-02-17 |
| 2024-09-30 | $303.97M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $397.39M derived: sum of 2 quarters · filed 2025-11-03 | $596.16M 10-Q · filed 2025-11-03 | $617.45M derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-06-30 | $93.42M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $292.18M 10-Q · filed 2025-08-05 | $313.48M derived: sum of 3 quarters · filed 2026-02-17 | $475.18M derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-03-31 | $198.76M 10-Q · filed 2025-05-06 | $220.06M derived: sum of 2 quarters · filed 2026-02-17 | $381.75M derived: sum of 3 quarters · filed 2026-02-17 | $381.75M derived: sum of 4 quarters · filed 2026-02-17 |
| 2023-12-31 | $21.29M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $182.99M derived: sum of 2 quarters · filed 2026-02-17 | $182.99M derived: sum of 3 quarters · filed 2026-02-17 | $292.91M 10-K · filed 2026-02-17 |
| 2023-09-30 | $161.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $161.70M derived: sum of 2 quarters · filed 2024-10-31 | $271.62M 10-Q · filed 2024-10-31 | $301.14M derived: sum of 4 quarters · filed 2025-02-18 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $109.92M 10-Q · filed 2024-08-06 | $139.44M derived: sum of 3 quarters · filed 2025-02-18 | $139.44M derived: sum of 4 quarters · filed 2025-02-18 |
| 2023-03-31 | $109.92M 10-Q · filed 2024-05-07 | $139.44M derived: sum of 2 quarters · filed 2025-02-18 | $139.44M derived: sum of 3 quarters · filed 2025-02-18 | $180.31M derived: sum of 4 quarters · filed 2025-02-18 |
| 2022-12-31 | $29.52M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-18 | $29.52M derived: sum of 2 quarters · filed 2025-02-18 | $70.39M derived: sum of 3 quarters · filed 2025-02-18 | $255.21M 10-K · filed 2025-02-18 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $40.87M derived: sum of 2 quarters · filed 2023-11-06 | $225.69M 10-Q · filed 2023-11-06 | $594.85M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-06-30 | $40.87M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $225.69M 10-Q · filed 2023-08-08 | $594.85M derived: sum of 3 quarters · filed 2024-02-20 | $636.28M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-03-31 | $184.81M 10-Q · filed 2023-05-09 | $553.98M derived: sum of 2 quarters · filed 2024-02-20 | $595.40M derived: sum of 3 quarters · filed 2024-02-20 | $716.35M derived: sum of 4 quarters · filed 2024-02-20 |
| 2021-12-31 | $369.16M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | $410.59M derived: sum of 2 quarters · filed 2024-02-20 | $531.53M derived: sum of 3 quarters · filed 2024-02-20 | $652.51M 10-K · filed 2024-02-20 |
| 2021-09-30 | $41.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $162.37M derived: sum of 2 quarters · filed 2022-11-08 | $283.35M 10-Q · filed 2022-11-08 | $348.05M derived: sum of 4 quarters · filed 2023-02-21 |
| 2021-06-30 | $120.95M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $241.93M 10-Q · filed 2022-08-09 | $306.62M derived: sum of 3 quarters · filed 2023-02-21 | $389.87M derived: sum of 4 quarters · filed 2023-02-21 |
| 2021-03-31 | $120.98M 10-Q · filed 2022-05-10 | $185.68M derived: sum of 2 quarters · filed 2023-02-21 | $268.93M derived: sum of 3 quarters · filed 2023-02-21 | $283.91M derived: sum of 4 quarters · filed 2023-02-21 |
| 2020-12-31 | $64.70M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-21 | $147.95M derived: sum of 2 quarters · filed 2023-02-21 | $162.93M derived: sum of 3 quarters · filed 2023-02-21 | $226.19M 10-K · filed 2023-02-21 |
| 2020-09-30 | $83.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-02 | $98.23M derived: sum of 2 quarters · filed 2021-11-02 | $161.49M 10-Q · filed 2021-11-02 | $309.67M derived: sum of 4 quarters · filed 2022-02-22 |
| 2020-06-30 | $14.98M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $78.24M 10-Q · filed 2021-08-09 | $226.41M derived: sum of 3 quarters · filed 2022-02-22 | $234.31M derived: sum of 4 quarters · filed 2022-02-22 |
| 2020-03-31 | $63.26M 10-Q · filed 2021-05-10 | $211.43M derived: sum of 2 quarters · filed 2022-02-22 | $219.33M derived: sum of 3 quarters · filed 2022-02-22 | |
| 2019-12-31 | $148.18M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-22 | $156.07M derived: sum of 2 quarters · filed 2022-02-22 | $389.76M 10-K · filed 2022-02-22 | |
| 2019-09-30 | $7.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-02 | $241.58M 10-Q · filed 2020-11-02 | ||
| 2019-06-30 | $233.68M 10-Q · filed 2020-08-10 | |||
| 2018-12-31 | $311.11M 10-K · filed 2021-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |